AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Novel Nanoliposomal Nitroglycerin Formulation for Cardiovascular Therapies

Technology Application

Novel formulation of NTG for potential use in conditions associated with the inflammatory process such as PAH, atherosclerosis, and diabetes A more potent formulation of NTG could be used in the current indications of chest pain and high blood pressure during surgery

Detailed Technology Description

None

Application No.

20180177724

Others

Background

Leukocyte-endothelial cell (EC) adhesion is a hallmark of the inflammatory process, and is associated with diseases such as pulmonary arterial hypertension (PAH), atherosclerosis, and diabetes. This adhesion is inhibited by endogenous EC-derived nitric oxide (NO), which is significantly impaired in the aforementioned conditions. Thus, NO-releasing nitrates are being investigated as anti-inflammatory therapies.

Nitroglycerin (NTG) is of particular interest among clinically-used nitrates because it spontaneously produces NO and also activates endothelial NO synthase (eNOS), the key NO-producing enzyme in ECs that is impaired in inflammatory conditions. However, NTG is not suitable for long-term clinical use due to loss of NTG sensitivity (tolerance) and endothelial dysfunction (cross-tolerance).

Related Materials

Ardekani & Ghosh, et al. Nonoliposomal Nitroglycerin Exerts Potent Anti-Inflamatory Effects. Scientific Reports 5, 16258 (2015).

Tech ID/UC Case

28752/2016-346-0

Related Cases

2016-346-0

Country/Region

USA

For more information, please click Here